All Outputs (3)

Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum (2021)
Journal Article
Nakafero, G., Grainge, M. J., Card, T., Taal, M. W., Aithal, G. P., Zhang, W., …Abhishek, A. (2022). Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum. Rheumatology, 61(7), 2783-2791. https://doi.org/10.1093/rheumatology/keab790

OBJECTIVE: To develop and validate a prognostic model for LEF discontinuation with abnormal blood test results. METHODS: Data from the Clinical Practice Research Datalink Gold and Aurum were used for model development and external validation, respect... Read More about Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum.

What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline? (2021)
Journal Article
Nakafero, G., Grainge, M. J., Card, T., Mallen, C. D., Zhang, W., Doherty, M., …Abhishek, A. (2021). What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?. Rheumatology, 60(12), 5785-5794. https://doi.org/10.1093/rheumatology/keab254

Objectives: To examine incidence of treatment changes due to abnormal blood-test results and, to explore rates of treatment changes due to liver, kidney and haematological blood-test abnormalities in autoimmune rheumatic diseases (AIRD) treated with... Read More about What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?.

?-blocker prescription is associated with lower cumulative risk of knee osteoarthritis and knee pain consultations in primary care: A propensity score-matched cohort study (2021)
Journal Article
Nakafero, G., Grainge, M. J., Valdes, A. M., Townsend, N., D. Mallen, C., Zhang, W., …Abhishek, A. (2021). β-blocker prescription is associated with lower cumulative risk of knee osteoarthritis and knee pain consultations in primary care: A propensity score-matched cohort study. Rheumatology, 60(12), 5686-5696. https://doi.org/10.1093/rheumatology/keab234

Objectives: To examine the association between ?-blocker prescription and first primary-care consultation for knee OA, hip OA, knee pain and hip pain. Methods: Data source: Clinical Practice Research Datalink. Participants aged ?40 years in receipt o... Read More about ?-blocker prescription is associated with lower cumulative risk of knee osteoarthritis and knee pain consultations in primary care: A propensity score-matched cohort study.